Sweeping doubts aside, Eli Lilly beats Regeneron to emergency OK — clearing low dose antibody for quick rollout
Eli Lilly has clinched the first emergency use authorization issued for an antibody against Covid-19, setting in motion a $1.2 billion deal to supply the feds with the drug — albeit at a dose that failed the primary endpoint in a key trial.
Prioritizing a reduction in Covid-19-related hospitalizations or visits to the ER, the FDA opened the door for physicians to give 700 mg/20 mL injections of the drug, dubbed bamlanivimab, to recenly diagnosed, non-hospitalized patients who don’t need extra oxygen due to the coronavirus infection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.